Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pharmacyclics, Inc.

http://www.pharmacyclics.com

Latest From Pharmacyclics, Inc.

Asia Deal Watch: Kelun Partners With Merck A Third Time, Optioning Rights To Seven ADCs

Already partnered on antibody-drug conjugates and a Phase III breast cancer candidate, Merck could pay up to $9.3bn under its third pact in 2022 with Kelun. Eisai divests Fycompa to Catalyst.

Deal Watch Business Strategies

The Medtech 100 Ranking: A Successful Year But Industry Must Tread Carefully In 2023

Medtech Insight’s just-published ranking of the leading global medtechs based on revenues reported for fiscal 2021 reveals a picture of an industry overwhelmingly in growth, despite – or in some cases because of – the persistent effects of the pandemic.

Medtech 100 Commercial

As Magrolimab AML Studies Chug Along, The Question Becomes How To Combine It

With an FDA hold lifted and enrollment moving quickly, physicians are looking at how to combine magrolimab with other treatments in patients with TP53-mutated AML. 

Clinical Trials Cancer

Finance Watch: No New IPOs, But Two Firms Take The SPAC Route

Public Company Edition: NewAmsterdam grossed $328m in its SPAC merger, while Liminatus may raise up to $316m in a new SPAC deal. Also, Intellia and Iveric grossed $300m each in follow-on offerings, bluebird sold a PRV for $102m and MEI ends zandelisib development resulting in layoffs.

Financing Business Strategies
See All

Company Information

UsernamePublicRestriction

Register